Nothing Special   »   [go: up one dir, main page]

WO2014009970A3 - Dispersion solide de linagliptine - Google Patents

Dispersion solide de linagliptine Download PDF

Info

Publication number
WO2014009970A3
WO2014009970A3 PCT/IN2013/000417 IN2013000417W WO2014009970A3 WO 2014009970 A3 WO2014009970 A3 WO 2014009970A3 IN 2013000417 W IN2013000417 W IN 2013000417W WO 2014009970 A3 WO2014009970 A3 WO 2014009970A3
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
solid dispersion
preparation
pharmaceutically acceptable
combination
Prior art date
Application number
PCT/IN2013/000417
Other languages
English (en)
Other versions
WO2014009970A2 (fr
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Kesireddy Subash Chander Reddy
Bandi Vamsi Krishna
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to US14/589,495 priority Critical patent/US9381199B2/en
Publication of WO2014009970A2 publication Critical patent/WO2014009970A2/fr
Publication of WO2014009970A3 publication Critical patent/WO2014009970A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une nouvelle dispersion solide amorphe de linagliptine combinée avec un excipient pharmaceutiquement acceptable, un procédé pour sa préparation et des compositions pharmaceutiques la comprenant.
PCT/IN2013/000417 2012-07-09 2013-07-08 Dispersion solide de linagliptine WO2014009970A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/589,495 US9381199B2 (en) 2012-07-09 2013-07-08 Linagliptin solid dispersion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ININ2780/CHE/2012 2012-07-09
INCH27802012 2012-07-09

Publications (2)

Publication Number Publication Date
WO2014009970A2 WO2014009970A2 (fr) 2014-01-16
WO2014009970A3 true WO2014009970A3 (fr) 2015-07-30

Family

ID=49916619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000417 WO2014009970A2 (fr) 2012-07-09 2013-07-08 Dispersion solide de linagliptine

Country Status (1)

Country Link
WO (1) WO2014009970A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381199B2 (en) 2012-07-09 2016-07-05 Hetero Research Foundation Linagliptin solid dispersion
US10253026B2 (en) * 2015-06-25 2019-04-09 Boenringer Ingelheim International GmbH Process for the preparation of (r)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1h-purine-2,6-dione
US11226114B2 (en) * 2016-05-03 2022-01-18 Carrier Corporation Inlet for axial fan
CN112961155A (zh) * 2021-03-16 2021-06-15 华北水利水电大学 一种利格列汀的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20100209506A1 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20110263617A1 (en) * 2008-09-10 2011-10-27 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20120046224A1 (en) * 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20110263617A1 (en) * 2008-09-10 2011-10-27 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20100209506A1 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120046224A1 (en) * 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome

Also Published As

Publication number Publication date
WO2014009970A2 (fr) 2014-01-16

Similar Documents

Publication Publication Date Title
IL279304A (en) History of cytotoxic benzodiazepines, preparations containing them and their uses
IL263780A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
WO2014076712A3 (fr) Dispersion solide de chlorhydrate de lurasidone
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
IL221952A (en) Annotations 2, 3-Dihydro-1h - Indene-1-Il-7,2- Diazaspiro [5.3] Noonan and Pharmaceuticals Containing Them
HUE037747T2 (hu) Nanostrukturált aprepirant készítmények, eljárások azok elõállítására és az azokat tartalmazó gyógyászati készítmények
WO2012068441A3 (fr) Sels d'intedanib et leurs formes à l'état solide
WO2015104658A3 (fr) Dispersion solide amorphe de dapagliflozine et procédé pour la préparation de dapagliflozine amorphe
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
HK1162262A1 (zh) 基料、含有該基料的產物、其製備方法及用途
WO2013164839A8 (fr) Forme amorphe d'apixaban, son procédé de préparation et compositions de celle-ci
WO2012085927A3 (fr) Compositions de tadalafil
IN2012DN02793A (fr)
IL212942A (en) History of Rifamycin, Methods of Preparation, Pharmaceutical Preparations Containing Them and Their Uses
HK1204615A1 (en) (1r,4r)7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof (1r4r)7--2-[222]-5-
WO2014009970A3 (fr) Dispersion solide de linagliptine
IL225440A (en) Cyclohexane derivatives, preparations containing them and their uses
IN2012CH01309A (fr)
WO2014105777A8 (fr) Sel de dichlohydrate de cobicistat
WO2014115169A3 (fr) Dispersion solide de crizotinib
WO2015044434A3 (fr) Fluoro-9-méthyl-β-carboline
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2014013511A3 (fr) Dispersion solide de rufinamide
WO2012139074A3 (fr) Migrastatines et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816209

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14589495

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13816209

Country of ref document: EP

Kind code of ref document: A2